Acquired Company
Omega Therapeutics was acquired by Pioneering Medicines 08-B, Inc. (an affiliate of Flagship Pioneering) in a bankruptcy sale closed on August 8, 2025.
Omega Therapeutics Inc is a pioneering biotechnology company dedicated to developing innovative epigenetic mRNA medicines targeting a wide array of diseases. Utilizing its proprietary Omega Epigenetics Engine, the company is poised to unlock the potential of the epigenome, driving advancements in genetics and personalized medicine. With a promising pipeline of therapeutics spanning multiple developmental stages, Omega Therapeutics stands at the forefront of precision healthcare, strategically addressing some of the most significant unmet medical needs. Its unwavering commitment to scientific excellence and strategic collaborations positions it as a key player in reshaping treatment paradigms for patients globally. Show more
20 ACORN PARK DRIVE, CAMBRIDGE, MA, UNITED STATES, 02140, USA
Market Cap
7.895M
52 Wk Range
$0.00 - $0.00
Previous Close
$0.14
Open
$0.14
Volume
N/A
Day Range
$0.14 - $0.14
Enterprise Value
0.00
Cash
30.38M
Avg Qtr Burn
-14.02M
Insider Ownership
1.67%
Institutional Own.
87.75%
Qtr Updated
09/30/24
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
OTX-2002 Details Cancer, Hepatocellular carcinoma, Liver cancer | Phase 2 Initiation |
